The 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America Guideline for the Management of Heart Failure includes 4 classes of medication for guideline-directed medical therapy. Guidance for sodium-glucose cotransporter-2 inhibitors (SGLT2is) is now included for some patients. Learn more about the burden of heart failure, and how the guidelines recommend incorporating these therapies to improve our patients’ quality of life in the CardioBites Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) series that was released between March 2024 and August 2024.
Videos in the Series
Support for this program was provided by an independent grant from Lexicon Pharmaceuticals, Inc.
About CardioBites
CardioBites are mobile-friendly, bite-sized videos providing focused education on important topics in the heart failure field. They can be watched anytime, anywhere on YouTube. No password. No barriers. Just easy access. Each CardioBites series is designed to educate physicians, scientists, nurses, nurse practitioners, pharmacists, and patients about the recent advances and emerging trends in Heart Failure. Learn More.